Randomized trial comparing 7 day and 5 day schedule of azacitidine for high-risk MDS -JALSG MDS212-

Authors
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2012
INTERVENTION: azacitidine 75mg/m2, 5 days azacitidine 75mg/m2, 7 days CONDITION: Myelodysplastic syndromes (RAEB and RAEB‐t in FAB classification) PRIMARY OUTCOME: 2‐year overall survival INCLUSION CRITERIA: (1) RAEB or RAEB‐t of MDS in FAB classification (2) Survival more than 3 months is expected (3) No previous treatment with azacitidine, chemotherapy, transplantation, or lenalidomide (4) 16‐years old or older (5) No candidate of hematopoietic stem cell transplantation (6) Performance status (ECOG) 0‐2 (7) Enough organ function (8) With written informed consent
Epistemonikos ID: e77a50c1dfa625803ea41ba518981990e546c20c
First added on: Aug 22, 2024